Pregnancy Outcomes in Patients Exposed to Intramuscular Interferon beta-1a (IM IFNβ-1a)

被引：0
|
作者：
Tomczyk, Sylvie [1 ]
Sperling, Bjorn [2 ]
机构：
[1] Biogen Idec Inc, Cambridge, MA USA
[2] Biogen Idec Inc, Weston, MA USA
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S30006
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Post-marketing pregnancy outcomes in patients exposed to intramuscular interferon-β-1a
    Tomczyk, S.
    Sperling, B.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 100 - 100
  • [2] SAFE AND EFFECTIVE USE OF THE SINGLE-USE INTRAMUSCULAR (IM) INTERFERON BETA-1A (IFNβ-1A) AUTOINJECTOR IN THE TREATMENT OF MULTIPLE SCLEROSIS (MS)
    Phillips, J. T.
    Tuccillo, D.
    Liu, S.
    Curnow, K.
    Deykin, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 537 - 537
  • [3] Analysis of Pregnancy Outcomes Following Exposure to Intramuscular Interferon Beta-1a: The AVONEX® Pregnancy Exposure Registry
    Weinstock-Guttman, Bianca
    Ross, Amy Perrin
    Planton, Jonathan
    White, Kurt
    Pandhi, Avni
    Greco, Andres
    Kumar, Achint
    Everage, Nicholas
    Vignos, Megan
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (04) : 503 - 511
  • [4] Analysis of Pregnancy Outcomes Following Exposure to Intramuscular Interferon Beta-1a: The AVONEX® Pregnancy Exposure Registry
    Bianca Weinstock-Guttman
    Amy Perrin Ross
    Jonathan Planton
    Kurt White
    Avni Pandhi
    Andres Greco
    Achint Kumar
    Nicholas Everage
    Megan Vignos
    Drugs - Real World Outcomes, 2023, 10 : 503 - 511
  • [5] Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFN beta-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration
    Alam, J
    McAllister, A
    Scaramucci, J
    Jones, W
    Rogge, M
    CLINICAL DRUG INVESTIGATION, 1997, 14 (01) : 35 - 43
  • [6] Characteristics and clinical outcomes of older patients with ms treated with peginterferon beta-1a or intramuscular interferon beta-1a in ms paths
    Hua, L. H.
    Liao, S.
    Hersh, C.
    Fitzgerald, K.
    Altincatal, A.
    Naylor, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 519 - 520
  • [7] Pregnancy outcomes in patients receiving IFN beta-1a for the treatment of multiple sclerosis
    Sandberg-Wollheim, MM
    Frank, D
    NEUROLOGY, 2005, 64 (06) : A127 - A127
  • [8] Real-world outcomes in patients with relapsing forms of multiple sclerosis treated with intramuscular interferon beta-1a or peginterferon beta-1a
    Salter, A.
    Lancia, S.
    Cutter, G.
    Fox, R.
    Marrie, R. A.
    Avila, R.
    Vignos, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 187 - 187
  • [9] Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis
    Sandberg-Wollheim, M
    Frank, D
    Goodwin, TM
    Giesser, B
    Lopez-Bresnahan, M
    Stam-Moraga, M
    Chang, P
    Francis, GS
    NEUROLOGY, 2005, 65 (06) : 802 - 806
  • [10] Cost-effectiveness of 44 mcg subcutaneous interferon beta-1a (scIFNβ1a) and 30 mcg intramuscular interferon beta-1a (imIFNβ1a) using clinical endpoints of disease activity
    Phillips, A. L.
    Edwards, N. C.
    Locklear, J. C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 421 - 421
12345